In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy
about
Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.Skeletal muscle characteristics are preserved in hTERT/cdk4 human myogenic cell lines.Eteplirsen in the treatment of Duchenne muscular dystrophyAntisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy.Correcting the NLRP3 inflammasome deficiency in macrophages from autoimmune NZB mice with exon skipping antisense oligonucleotides.Short (16-mer) locked nucleic acid splice-switching oligonucleotides restore dystrophin production in Duchenne Muscular Dystrophy myotubes.Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy.Antisense oligonucleotides: the next frontier for treatment of neurological disorders.Designing Effective Antisense Oligonucleotides for Exon Skipping.A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.Muscle dysfunction caused by loss of Magel2 in a mouse model of Prader-Willi and Schaaf-Yang syndromes.Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts.Shorter Phosphorodiamidate Morpholino Splice-Switching Oligonucleotides May Increase Exon-Skipping Efficacy in DMDIdentification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy
P2860
Q33594805-88FD0155-6E34-4817-920E-DF7DAA35AF61Q37487702-8C05657F-5FEE-43A2-A35A-2FD42B1616B5Q37682676-C49297CD-F318-4BEA-B208-FEF3236FB2C7Q38958094-501A84F3-506F-48FB-BA72-98115ED1609BQ39342422-3FA8FCB1-C6DC-48CD-98A9-541E1371B0CAQ40809647-7CA4D074-6DAF-441F-AECE-677C13B36D0CQ41106058-63E576B9-11CC-4FB1-8C67-A3ADC9C0629FQ45945952-19B9C54A-7DBB-48A6-A06C-8AA6C7BEBBFDQ47158837-9A5DE76B-74C3-45F9-BBC0-561273761EA3Q47344432-71A8E182-D389-46C8-B137-6A574E05E8C0Q47606988-E3D2847F-69FC-4CFF-BB93-D36F54E84B49Q50018682-0B8B3AB0-67D8-45A4-859D-159FC954D9ACQ51629774-DC7B44E4-5295-4F27-9034-D58144FA48EBQ55284165-C9684D4F-4116-43FB-80FC-DA235983939CQ58577259-C758F304-7C5E-4F80-A5FB-0E1C6DA44F96Q59129603-9FC4648F-0EEF-459F-9F69-2AFA36E12175
P2860
In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
In silico screening based on p ...... in Duchenne muscular dystrophy
@ast
In silico screening based on p ...... in Duchenne muscular dystrophy
@en
type
label
In silico screening based on p ...... in Duchenne muscular dystrophy
@ast
In silico screening based on p ...... in Duchenne muscular dystrophy
@en
prefLabel
In silico screening based on p ...... in Duchenne muscular dystrophy
@ast
In silico screening based on p ...... in Duchenne muscular dystrophy
@en
P2860
P50
P1433
P1476
In silico screening based on p ...... in Duchenne muscular dystrophy
@en
P2093
Luis Garcia
Toshifumi Yokota
P2860
P304
P356
10.1371/JOURNAL.PONE.0120058
P407
P577
2015-03-27T00:00:00Z